[Multiple myeloma preceding myelodysplastic syndrome with eosinophilia and der (1;7)].
Multiple myeloma (IgG kappa + IgA kappa type, clinical stage IA) was diagnosed in a 82-year-old woman in January 1986. Chemotherapy (melphalan, prednisolone, vindesine, cyclophosphamide), caused prolonged myelosuppression. Therefore she was given other treatment. In October 1992, her peripheral blood examination demonstrated 2% blastic cells and 12% eosinophils. Bone marrow aspiration showed dysplastic features of trilineage blood cells with 4.8% myeloblasts. The karyotype of bone marrow cells from this patients was 47, XX, +der(1)t(1;7) (p11;p11), -7, +8. A diagnosis of therapy-related myelodysplastic syndrome (refractory anemia) was established. Eleven months after diagnosis of myelodysplastic syndrome, she is alive without leukemic transformation.
Matano
S
S
Department of Internal Medicine, Tonami General Hospital.
Kobayashi
K
K
Nakamura
S
S
Yoshida
T
T
D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002878:Chromosomes, Human, Pair 1; D002897:Chromosomes, Human, Pair 7; D003520:Cyclophosphamide / Q000009:adverse effects; D004802:Eosinophilia / Q000139:chemically induced / Q000235:genetics*; D005260:Female; D006801:Humans; D008558:Melphalan / Q000009:adverse effects; D009101:Multiple Myeloma / Q000188:drug therapy*; D009190:Myelodysplastic Syndromes / Q000139:chemically induced / Q000235:genetics*; D011239:Prednisolone / Q000009:adverse effects; D014178:Translocation, Genetic; D014751:Vindesine / Q000009:adverse effects
D003520:Cyclophosphamide; D011239:Prednisolone; D008558:Melphalan; D014751:Vindesine